I’ve said from the beginning that BiDil is essentially two generics combined into an expensive brand name drug. Well the sales are showing that this approach isn’t working:
As the WSJ reported earlier this year, groups including the American Heart Association and the American College of Cardiology say there’s no evidence that prescribing BiDil works any better than prescribing both of its constituent generics, isosorbide dinitrate and hydralazine. Yet BiDil costs insurers between $1,400 and $2,800 per year, while the generics can cost less than $100.
